Beta Bionics, Inc.

NASDAQ:BBNX

Medical - Equipment & Services

Healthcare
$14.33 +3.18%

+$0.42 today

Market cap
$644.70M
Beta
3.39
P/E (TTM)
-9.1
EPS (TTM)
-$1.50
52W Low $8.80High $32.71

Volume 1.38M

Average 0.99M

BBNX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Beta Bionics, Inc.NASDAQ: BBNX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $10.36M rose 36.4% year over year, ahead of the +32.7% change in trailing-twelve-month research & development. Sequentially, it rose 2.2% from the prior quarter. Over 3 fiscal years it compounded at +3.4% a year.

Context

  • Research & development amounted to 34.7% of revenue in FY2025, down 5.5 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +36.4% holds above the trailing-twelve-month pace of +32.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.36M+2.2% QoQ
Last fiscal yearDec 2025
$34.79M+32.9% YoY
LTMMar 2026
$37.56M+32.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+36.4%——
1 year+32.9%——
3-year CAGR+3.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
34.79M USD
Year-over-year change
+32.9%
3-year CAGR
+3.4%

Research & Development vs competitors

How BBNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +32.7% is the 3rd highest of 7, against a peer median of +17.3%.
  • Research & development amounts to 34.1% of revenue for BBNX, versus a peer median of 15.6%.
BBNX Competitors
Research & Development for BBNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 58.11B DKK+28.3%+29.3%17.6%
DXCMDexCom, Inc.LTM Jun 2026$604M USD+6.3%+7.4%12.2%
MMEDMiniMed Group, Inc. Common StockLTM Jul 2026$439M USD—+1.5%13.6%
PODDInsulet CorporationLTM Jun 2026$345.9M USD+39.2%+18.7%11.3%
TNDMTandem Diabetes Care, Inc.LTM Mar 2026$188.1M USD-32.4%+0.9%18.3%
MNKDMannKind CorporationLTM Mar 2026$72.56M USD+54.7%+49.8%20.1%
BBNXBeta Bionics, Inc.LTM Mar 2026$37.56M USD+32.7%+3.4%34.1%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$5.77M USD-21.5%-38.7%—
Peer median (excluding BBNX) —+17.3%+7.4%15.6%

Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue179K12M65.12M100.25M
Cost of Revenue05.69M29.24M44.71M
Gross Profit179K6.31M35.89M55.54M
Gross Margin100.0%52.6%55.1%55.4%
Research & Development31.43M17.94M26.18M34.79M
Selling, General & Admin33.5M24.22M54.96M92.43M
Operating Expenses66.02M42.16M81.14M127.22M
Depreciation & Amortization1.35M1.23M1.15M2.88M
EBITDA(63.4M)(42.87M)(53.61M)(70.32M)
EBITDA Margin-35418.4%-357.4%-82.3%-70.1%
Operating Income(65.84M)(35.85M)(45.25M)(71.68M)
Operating Margin-36784.4%-298.9%-69.5%-71.5%
Interest Income196K1.78M3.91M10.93M
Interest Expense14K000
Other Income / Expenses1.09M(8.25M)(9.51M)(1.52M)
Income Before Tax(64.75M)(44.1M)(54.76M)(73.2M)
Pre-Tax Margin-36173.7%-367.6%-84.1%-73.0%
Income Tax Expense0001K
Net Income(64.75M)(44.1M)(54.76M)(73.2M)
Net Margin-36173.7%-367.6%-84.1%-73.0%
EPS (Basic)(12.96)(8.31)(8.60)(1.81)
EPS (Diluted)(12.96)(8.31)(8.60)(1.81)
Weighted Avg Shares5M5.3M6.37M40.53M
Weighted Avg Shares (Diluted)5M5.3M6.37M40.53M

Beta Bionics, Inc.

NASDAQ:BBNX

Intrinsic Alpha fair value

Locked

Current Price

$14.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.